Evolving Technology Platforms in Pharma-Biotech

The road ahead toward precision medicine

News provided by

Dec 14, 2015, 04:11 ET

LONDON, Dec. 14, 2015 /PRNewswire/ -- The continued development of new treatments associated with the demographic trends and public health considerations is essential. The biopharmaceutical industry is one of the most research intensive sectors in developed nations. Investments are more than USD 125 billion, especially in early stages development phases, including the processes of discovering and developing new medicines.

Biopharmaceutical innovation has played a major role in the improvement of both length and quality of life during the past decade, considerably reducing the disease burden for individuals and the society. Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for precision medicine for the upcoming years. Indeed, the promise of personalized medicine is becoming a reality generating notable improvements in human health and the potential to reduce the socioeconomic burden of disease. Evolving Technology Platforms in Pharma-Biotech

This research service (RS) depicts the current landscape of biopharmaceutical development, focusing on medicines that have progressed beyond early stage development and have recently entered clinical testing in human volunteers or first-in-human studies. The RS also includes:

R&D portfolio and budgetary analysis
Environmental analysis, depicting the key technical challenges, key business challenges, and emerging market needs
Industry best practices and strategic insights, measuring performance, assessment of partnerships and alliances and R&D pipeline by milestones
Strategic evaluation of R&D portfolio

Research Scope

Research Focus

Report coverage and evaluation
The continued development of new treatments associated with the demographic trends and public health considerations is essential. The biopharmaceutical industry is one of the most research intensive sectors in developed nations. Investments are more than USD 125 billion, especially in early stages development phases, including the processes of discovering and developing new medicines. Biopharmaceutical innovation has played a major role in the improvement of both length and quality of life during the past decade, considerably reducing the disease burden for individuals and the society. Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for precision medicine for the upcoming years. Indeed, the promise of personalized medicine is becoming a reality generating notable improvements in human health and the potential to reduce the socioeconomic burden of disease.

This research service (RS) depicts the current landscape of biopharmaceutical development, focusing on medicines that have progressed beyond early stage development and have recently entered clinical testing in human volunteers or firstin-human studies. The RS also includes:
- R&D portfolio and budgetary analysis
- Environmental analysis, depicting the key technical challenges, key business challenges, and emerging market needs
- Industry best practices and strategic insights, measuring performance, assessment of partnerships and alliances and R&D pipeline by milestones
- Strategic evaluation of R&D portfolio

Key Findings
The Biopharmaceutical Landscape
Current behavior of most top-tier biopharmaceutical companies
- The process of developing a new medicine is long and complex, and highly risky in nature due to the possibility of failures at each step in the process. As an overall estimation, an average cost to yield a single FDA-approved drug is approximately USD billion, and the entire research and development and FDA approval process time lasts between and years. Therefore, the need to reduce risk and guarantee efficient results is critical in our times.
- Factors affecting the cost, duration, and uncertainties associated with clinical trials, are continuously challenging the current drug development economic model and need to be noted and overcome. Interdisciplinary work, involving not only scientists from industry, government, and academia developing new tools and methods to improve R&D efficiency and designing new computer-based models and in silico approaches to predict how a candidate drug is absorbed, distributed, and eliminated from the body, but also, financial managers and economists who help to develop better predictive models, is gaining attention in this decade. The underlying goal is to improve the efficiency of the drug development process by narrowing the patient population where the drug has the best chance of success through precision medicine approaches, as well as, by eliminating candidate drugs before risky and costly clinical trials take place.
- Candidate drugs in clinical trials holding better chance of success, and involving a smaller number of clinical trials are expected to contribute to improve safety and efficacy. Accordingly, researchers are collaborating on pre-competitive research in areas such as biomarkers in order to accelerate research progress.
- Most top-tier biopharmaceutical companies have launched their open innovation programs to foster scientific innovation and collaborations worldwide. Broadly, though with some differences from one company to another, these programs consist of the development of opportunities with external collaborators through the free of charge access to the company's tool compounds to conduct preclinical research in multiple therapeutic areas, evaluating multiple mechanisms of action (MoA). A Material Transfer Agreement is usually signed to protect the interests of both parties.
- Biomanufacturing in novel hubs such as Singapore's Biopolis and Tuas Biomedical Parks constitutes one of the major trends for top-tier biopharmaceutical companies at present.
Download the full report: https://www.reportbuyer.com/product/3467046/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com